頁籤選單縮合
題 名 | Efficacy and Safety of Olanzapine Versus Haloperidol in the Treatment of Taiwanese Schizophrenia Patients=比較Olanzapine或Haloperidol治療精神分裂症的療效與安全性的雙盲研究 |
---|---|
作 者 | 洪成志; 鄭若瑟; 黃宗正; 陳映雪; 郭錫卿; 藍先元; 李鶯喬; 張文和; 胡海國; | 書刊名 | 臺灣精神醫學 |
卷 期 | 15:3 2001.09[民90.09] |
頁 次 | 頁184-193 |
分類號 | 418.21 |
關鍵詞 | 精神分裂症; Schizophrenia; Olanzapine; Haloperidol; |
語 文 | 英文(English) |
中文摘要 | 目的:Olanzapine是最近幾年才上市的非典型抗精神病藥物。這個多中心的臨床試驗探討olanzapine對台灣的精神分裂症患者的療效與副作用。方法:以隨機與雙盲的方法讓54名精神分裂症患者服用14週的olanzapine(N=26,平均劑量14.2mg/day) 或haloperidol(N=28,平均劑量13.4mg/day)。結果:Olanzapine在PANNS的正性量表 (p=.021) 及不自主運動量表 (AIMS) (p=.011) 上的的進步優於haloperidol。Olanzapine組有54.2%的患者BPRS總分降低40%以上,haloperidol組則只有28.6%。Olanzapine組的患者所發生的錐體外徑副作用、激躁不安及amblyopia的比率比haloperidol少 (p<0.05),但是haloperidol組的患者體重增加的情形比較少 (p=.002)。結論:臺灣的精神分裂症患者對5到20mg/day的olanzapine有不錯的接受度與療效反應。 |
英文摘要 | Objective: Olanzapine is a novel atypical antipsychotic agent that became available in 1998 in Taiwan. To investigate the safety and efficacy profile of olanzapine in Taiwanese patients with schizophrenia, a prospective multi-center trial was conducted. Methods: In this 14-week, randomized, double-blinded study, 54 schizophrenic patients in Taiwan were given olanzapine (N=26; mean modal dose 14.2 mg/day) or haloperidol (N=28; mean modal dose 13.4 mg/day). Results: Olanzapine was significantly superior to haloperidol in improving baseline to endpoint mean scores (p=.021) on the Positive Scale of the Positive and Negative Symptom Scale (PANSS) and the Abnormal Involuntary Movement Scale (AIMS) (p=.011). There were no statistically significant differences between olanzapine and haloperidol on the other rating scales of efficacy and extrapyramidal symptoms (EPS). The response rate (a decrease of 40% on BPRS total score) was 54.2% with olanzapine compared to 28.6% with haloperidol. Olanzapine-treated patients had significantly lower incidences of treatment-emergent EPS, agitation, and amblyopia (p .050) than haloperidol-treated patients, while haloperidol-treated patients experienced significantly less weight gain (p=.002). Conclusion: Olanzapine is an effective and well tolerated agent for the treatment of Taiwanese patients with schizophrenia. The increased body weight under olanzapine treatment deserves clinical attention. |
本系統中英文摘要資訊取自各篇刊載內容。